Quick Answer
PROCEPT BioRobotics Corp reported Cash And Cash Equivalents At Carrying Value of $286.50 million for the year ending 2025.
- PROCEPT BioRobotics Corp showed a decrease of -14.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PROCEPT BioRobotics Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $113.35 million | Q1 2021: $86.12 million | Q2 2021: $159.22 million | Q3 2021: $320.48 million | Q1 2022: $284.29 million | Q2 2022: $269.81 million | Q3 2022: $249.22 million | Q1 2023: $180.97 million | Q2 2023: $149.69 million | Q3 2023: $287.09 million | Q1 2024: $225.58 million | Q2 2024: $214.09 million | Q3 2024: $196.76 million | Q1 2025: $316.21 million | Q2 2025: $302.72 million | Q3 2025: $294.28 million.
- Over the full 6 years of available data (2020 to 2025), PROCEPT BioRobotics Corp's Cash And Cash Equivalents At Carrying Value has grown by 186.1%.
- Historical annual values: Fiscal year 2025: $286.50 million | Fiscal year 2024: $333.73 million | Fiscal year 2023: $257.22 million | Fiscal year 2022: $221.86 million | Fiscal year 2021: $304.32 million | Fiscal year 2020: $100.13 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: